106
Participants
Start Date
July 23, 2020
Primary Completion Date
November 16, 2021
Study Completion Date
November 16, 2022
Mirvetuximab Soravtansine
Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Mater Misericordiae University Hospital, Dublin
St. James's Hospital, Dublin
Beaumont Hospital, Dublin
Cliniques Universitaires Saint Luc - lnstitut Roi Albert II, Brussels
"MHAT Serdika", Sofia
Royal North Shore Hospital, St Leonards
UZ Leuven, Leuven
Peninsula and South Eastern Haematology & Oncology Group, Frankston
ICON Cancer Care, Auchenflower
St John of God Subiaco Hospital, Subiaco
Ospedale S.Maria della Misericordia, Perugia
Centre Hopsitalier de l'Ardenne, Libramont
UZ Gent, Ghent
Mount Sinai Health System, New York
Istituto Oncologico Candiolo, Candiolo
Memorial Sloan-Kettering Cancer Center, New York
Ziv Medical Center, Safed
Hospital Reina Sofia de Cordoba, Córdoba
Hospital Teresa Herrera - Complejo Hospitalario Universitario A Coruna, A Coruña
Institut Català d'Oncología de Girona, Girona
IEO Istituto Europeo di Oncologia, Milan
Azienda Ospedaliera Ospedale Niguarda Ca'Granda, Milan
Maryland Oncology Hematology, P.A., Rockville
Azienda Socio Santaria Territoriale degli Spedali Civili di Brescia, Brescia
Clinica Universidad de Navarra, Madrid
MD Anderson Cancer Centre, Madrid
Hospital Clínico Universitario San Carlos, Madrid
Hospital La Paz, Madrid
Hospital Clinico Universitario Virgen de la Arrixaca, Murcia
Northside Hospital, Atlanta
Florida Cancer Specialists Panhandle, Tallahassee
Florida Cancer Specialists Research, West Palm Beach
University of South Florida, Tampa
Sarasota Memorial Health Care System, Sarasota
UMG Frauenklinik Robert-Koch-Str. 40, Göttingen
Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville
Policlinico S. Orsola-Malpighi, Bologna
Norton Cancer Institute, Louisville
KEM, Essen
Hospital Clinico Universitario de Valencia, Valencia
Instituto Valenciano de Oncologia, Valencia
St. Vincent Gynecologic Oncology, Indianapolis
Froedtert and the Medical College of Wisconsin Department of Obstetrics & Gynecology, Milwaukee
University of Wisconsin Carbone Cancer Center, Madison
Hinsdale Hospital, Hinsdale
Midwest Oncology Associates/Sarah Cannon, Kansas City
University of Kansas Cancer Center, Westwood
Universitätsmedizin Mannheim, Mannheim
Women's Cancer Center, Covington
Texas Oncology, P.A. - Tyler, Tyler
Kaplan Medical Center, Rehovot
Texas Oncology, P.A. - Fort Worth Cancer Center, Fort Worth
USOR: Texas Oncology - The Woodlands, Gynecologic Oncology, The Woodlands
Texas Oncology, P.A. - Sugar Land, Sugar Land
Texas Oncology, P.A. - McAllen, McAllen
Texas Oncology-Austin Central, Austin
Rocky Mountain Cancer Centers, Littleton
Fondazione IRCCS Istituto Nazionale dei Tumori, Napoli
Arizona Oncology Associates, Phoenix
Istituto Nazionale Tumori- G. Pascale, Napoli
Center of Hope at Renown Medical Center, Reno
City of Hope Medical Center, Duarte
Shaare Zedek Medical Center, Jerusalem
California Cancer Associates (cCARE), Fresno
California Pacific Medical Center Research Institute, San Francisco
Stanford School of Medicine, Palo Alto
Ospedale Cannizzaro di Catania, Catania
Kadlec Clinic Hematology and Oncology, Kennewick
Meir Medical Center, Kfar Saba
Sheba Medical Center, Ramat Gan
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Holy Name Medical Center, Teaneck
CHU UCL Namur/Site Sainte Elisabeth, Namur
Všeobecná fakultní nemocnice v Praze, Prague
Cork University Hospital, Cork
Bon Secours Hospital, Cork
University Hospital Waterford, Waterford
Rambam Medical Center, Haifa
Hadassah Ein Kerem Medical center, Jerusalem
Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma
Specjalistyczna Przychodnia Lekarska Medicus, Chorzów
Mazurskim Centrum Onkologiiw Olsztynie, Olsztyn
Instytut Centrum Zdrowia Matki Polki, Lodz
Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Quirón Dexeus, Barcelona
Vall d'Hebron Institute of Oncology, Barcelona
lnstitut Catala d' Oncologia L' Hospitalet, Barcelona
Corporació Sanitaria Parc Taulí, Sabadell
Lead Sponsor
ImmunoGen, Inc.
INDUSTRY